Climacteric

An independent guide to the menopause transition

Editorial policy

Sources & Editorial Policy

The evidence behind this guide, and how each page is reviewed.

Principal sources

  1. Davis SR, Taylor S, Hemachandra C, et al. The 2023 Practitioner's Toolkit for Managing Menopause. Climacteric. 2023;26(6):517–536.
  2. Women's Health Initiative (WHI) randomized trials of menopausal hormone therapy.
  3. NORA (National Osteoporosis Risk Assessment) study.
  4. U.S. Food and Drug Administration prescribing information for fezolinetant (Veozah, 2023) and elinzanetant (Lynkuet, 2025).
  5. U.S. Food and Drug Administration. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. Press announcement, November 10, 2025.

Sources for the expanded references

  1. Santen RJ, Heitjan DF, Gompel A, et al. Approach to Managing a Postmenopausal Patient. Journal of Clinical Endocrinology & Metabolism. 2020;105(12):3792–3806. Supplied article (PDF)

The companion references explain concepts from this dated clinical review. Older numerical treatment thresholds are not presented as current recommendations. Consult current guidance and your clinician for individual treatment decisions.

Review and dating

The original guide retains its physician-review attribution and review date. New companion references identify their underlying source dates without claiming a new medical review. Journal updates remain drafts until an approved editor reviews and publishes them.